View the new provider IRIS web page
Attention VFC Providers:
Vaccine inventory is currently being added to IRIS.
Your user lists will be faxed, to the immunization contact in your office, as soon as your organization’s inventory has been received and entered. We apologize for any inconvenience.
If you have questions, please contact the IRIS Help Desk at 208-334-5995 or iris@dhw.idaho.gov.
Access to IRIS is restricted to view only.VFC Providers only: If you have not submitted your inventory counts, please do so by 10am PST on Monday, February 27. Additionally, user access lists must also be submitted by Monday, February 27 at 10am PST. Failure to do so will prohibit access to IRIS to input vaccines or make vaccine orders.
Brand Choice
VFC Providers only: If you have not submitted your inventory counts, please do so by 10am PST on Monday, February 27. Additionally, user access lists must also be submitted by Monday, February 27 at 10am PST. Failure to do so will prohibit access to IRIS to input vaccines or make vaccine orders.
Changes to vaccine brand choice may be requested during the month of January 2012. Changes must be submitted in writing by completing a vaccine brand choice form and submitting the form to the Idaho Immunization Program or by sending an email to IIP@dhw.idaho.gov by Tuesday, January 31, 2012.
ACIP Recommends HPV4 for Male
On Tuesday, October 15, 2011, the Advisory Committee on Immunization Practices (ACIP) voted to recommend the routine vaccination of males 11 and 12* years with 3 doses of quadrivalent human papillomavirus (HPV4) vaccine (Gardasil®). ACIP also recommends the vaccination could begin as young as 9 years of age and that boys and young men 13 to 21 years of age who have not already received the vaccine should be vaccinated.
HPV4 (Gardasil®) male permissive recommendation was added to the Vaccines for Children (VFC) program in October 2009. In Idaho, all state-supplied Gardasil® vaccine should be used to vaccinate VFC-only eligible males 9 through 18 years of age (generally at age 11 or 12 years of age). If a male patient is non-VFC eligible you may not use your state-supplied HPV vaccine (Gardasil®).
The general HPV vaccine (Gardasil®) for males will be reviewed in the spring of 2012 by the Vaccine Assessment Board and may be included in the assessment for universal coverage.
*The greatest impact can be had when the vaccine is given at ages 11 – 12 years where there is a better immune response compared with older ages. The vaccine is most effective when it is given before there is exposure to the virus.